Biocon Share Price Target 2024, 2025 to 2030

Biocon Limited, founded in 1978 by Kiran Mazumdar-Shaw, is a leading biopharmaceutical company headquartered in Bangalore, India. With a global presence, Biocon manufactures generic active pharmaceutical ingredients (APIs) distributed across 120 countries, including key markets like the United States and Europe. Known for its biosimilar insulins, antibodies, and novel biologics, Biocon serves diverse medical needs worldwide. In India, its product range spans metabolics, oncology, immunotherapy, and nephrology, featuring renowned brands like INSUGEN, BASALOG, and CANMAb. Additionally, Biocon’s subsidiary, Syngene International Limited, operates as a contract research and development organization, enhancing the company’s research capabilities.

History of Biocon

Established in 1978 by Kiran Mazumdar with just Rs. 10,000, Biocon swiftly emerged as a global leader in biopharmaceuticals. Notable milestones include pioneering enzyme exports to the US and Europe in 1979 and securing USFDA approval for lovastatin production in 2001. Over the years, strategic collaborations and expansions propelled Biocon’s growth, leading to breakthroughs like the development of human insulin on a Pichia expression system and the launch of BIOMAb EGFR for cancer treatment. Key partnerships with global players like Abbott and Amgen further solidified its position.

In 2021, Biocon Biologics partnered with the Serum Institute of India to commercialize vaccines and biological drugs, amplifying its impact on public health. The acquisition of Viatris’ biosimilar assets in 2022 bolstered its standing in the biosimilars market, underscoring its commitment to advancing healthcare globally. Throughout its journey, Biocon has remained dedicated to innovation, shaping the biopharmaceutical landscape and improving patient outcomes worldwide.

Biocon Reports 57% Decline in Q4 Net Profit, Achieves Billion-Dollar Milestone in Biologics Segment

  • Biocon’s consolidated net profit for Q4 FY24 declined by 57% to Rs 136 crore due to higher expenses.
  • Total revenue in the fourth quarter saw a marginal increase to Rs 3,966 crore compared to the same period last year.
  • Total expenses for Q4 rose to Rs 3,635 crore, reflecting the challenging operational environment.
  • However, for the fiscal year ending March 31, 2024, Biocon witnessed a significant rise in consolidated net profit to Rs 1,022 crore compared to the previous fiscal year.
  • Total revenue for the fiscal year surged to Rs 15,621 crore, showcasing steady growth in performance.
  • The strong performance of the Biologics segment was a notable highlight, achieving a billion-dollar annual revenue milestone.
  • Increased market shares and significant volume growth in key markets like the US, Europe, and emerging markets contributed to the positive momentum in the biosimilars business.
  • Biocon’s strategic initiatives, including debt reduction and long-term collaborations for product distribution in India, contributed to its transformational journey in FY24.
  • The company’s board recommended a final dividend of 50 paise per share for the fiscal year, reflecting its commitment to shareholders amidst challenging market conditions.

How to Buy Biocon’s Shares in India?

You can buy Biocon shares in India by opening a trading account with a broker. You will need to provide your personal details, such as your PAN number, bank details, and other personal documents. Once the trading account is opened, you can buy Biocon shares using the broker’s online trading platform. You can also buy Biocon shares through a mutual fund or a portfolio management service. Some online platforms to buy shares are Zerodha, Sharekhan, and Upstox.

Biocon’s Share Price Prediction 2024 to 2030

Biocon’s Share Price Target for 2024

When Maximum Price Minimum Price
May 2024 318.60 277.05
June 2024 330.07 287.02
July 2024 326.77 284.15
August 2024 339.84 295.52
September 2024 353.44 307.34
October 2024 346.51 301.31
November 2024 360.37 313.36
December 2024 363.97 316.50

As we step into 2024, Biocon’s stock prices are projected to vary each month. In May 2024, Biocon’s maximum price is expected to be ₹318.60, while the minimum price will be ₹277.05. By December 2024, the maximum price is anticipated to reach ₹363.97, with the minimum price at ₹316.50.

Biocon’s Share Price Prediction for 2025

When Maximum Price Minimum Price
January 2025 367.61 282.78
February 2025 371.32 285.63
March 2025 379.12 291.63
April 2025 375.37 288.75
May 2025 364.44 280.34
June 2025 380.84 292.95
July 2025 373.37 287.21
August 2025 384.92 296.09
September 2025 389.53 299.64
October 2025 399.66 307.43
November 2025 409.65 315.12
December 2025 428.09 329.30

As we progress through 2025, Biocon’s stock prices are expected to exhibit monthly fluctuations. In January 2025, Biocon’s maximum price will be ₹367.61, while the minimum price will be ₹282.78. By December 2025, the maximum price is projected to reach ₹428.09, with the minimum price at ₹329.30.

Biocon’s Share Price Target for 2026

When Maximum Price Minimum Price
January 2026 440.93 339.18
February 2026 429.91 330.70
March 2026 438.51 337.31
April 2026 447.45 344.20
May 2026 443.02 340.79
June 2026 454.10 349.31
July 2026 445.20 342.46
August 2026 458.97 353.05
September 2026 468.14 360.11
October 2026 480.32 369.47
November 2026 492.32 378.71
December 2026 504.63 388.18

Biocon’s Share Price Target for 2027

When Maximum Price Minimum Price
January 2027 509.68 392.06
February 2027 522.75 402.11
March 2027 543.13 417.80
April 2027 532.48 409.60
May 2027 516.98 397.67
June 2027 540.24 415.57
July 2027 529.65 407.42
August 2027 546.03 420.02
September 2027 565.14 434.72
October 2027 579.83 446.02
November 2027 594.33 457.17
December 2027 609.19 468.60

Biocon’s Share Price Target for 2028

When Maximum Price Minimum Price
January 2028 621.37 477.98
February 2028 637.30 490.23
March 2028 662.16 509.35
April 2028 649.17 499.36
May 2028 630.27 484.82
June 2028 658.63 506.64
July 2028 645.71 496.70
August 2028 665.68 512.06
September 2028 688.98 529.99
October 2028 706.90 543.77
November 2028 724.57 557.36
December 2028 742.68 571.29

Biocon’s Share Price Target for 2029

When Maximum Price Minimum Price
January 2029 757.54 582.72
February 2029 776.96 597.66
March 2029 807.26 620.97
April 2029 791.43 608.79
May 2029 768.38 591.06
June 2029 802.96 617.66
July 2029 787.21 605.55
August 2029 811.56 624.28
September 2029 839.97 646.13
October 2029 861.80 662.93
November 2029 883.35 679.50
December 2029 905.43 696.49

Biocon’s Share Price Prediction for 2030

When Maximum Price Minimum Price
January 2030 923.54 710.42
February 2030 947.22 728.63
March 2030 984.16 757.05
April 2030 964.87 742.21
May 2030 936.76 720.59
June 2030 978.92 753.01
July 2030 959.72 738.25
August 2030 989.41 761.08
September 2030 1,024.04 787.72
October 2030 1,050.66 808.20
November 2030 1,076.93 828.41
December 2030 1,103.85 849.12

As we move through 2030, Biocon’s share prices are projected to show monthly variations. In January 2030, Biocon’s maximum share price will be ₹923.54, while the minimum will be ₹710.42. By December 2030, the maximum share price is expected to reach ₹1,103.85, with the minimum at ₹849.12.

Biocon Financial Condition: Last 5 Years

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Sales + 6,300 7,143 8,184 11,174 14,756
Expenses + 4,725 5,562 6,391 8,762 11,541
Operating Profit 1,575 1,581 1,793 2,412 3,214
OPM % 25% 22% 22% 22% 22%
Other Income + 228 260 72 18 854
Interest 65 58 68 419 974
Depreciation 552 715 814 1,113 1,569
Profit before tax 1,186 1,068 983 897 1,525
Tax % 27% 21% 22% 28% 15%
Net Profit + 871 846 772 643 1,298
EPS in Rs 6.24 6.17 5.4 3.85 8.52
Dividend Payout % 0% 0% 9% 39% 6%

Biocon’s financial performance over the years from March 2020 to March 2024 shows a steady increase in sales and operating profit. Sales grew from ₹6,300 crore in March 2020 to ₹14,756 crore in March 2024. Expenses also increased, reaching ₹11,541 crore in March 2024, leading to an operating profit of ₹3,214 crore with a consistent OPM of 22%.

Despite fluctuations in other income and rising interest and depreciation costs, Biocon’s profit before tax rose to ₹1,525 crore in March 2024. The company’s net profit improved significantly to ₹1,298 crore, and the EPS increased from ₹6.24 in March 2020 to ₹8.52 in March 2024.

Additionally, the tax rate decreased to 15% in March 2024, contributing to the higher net profit. However, the dividend payout varied, peaking at 39% in March 2023 before dropping to 6% in March 2024.

Finances rule

Also Read

FAQs

Will Biocon stock price grow in 2024?

Yes, Biocon stock price is expected to grow in 2024. The company’s current share price is around Rs 305, and analysts have estimated that Biocon price will reach ₹363.97 by the end of 2024.

What future is anticipated for Biocon in 2025?

Analysts expect Biocon’s stock price to reach Rs 428.09 by the end of 2025. Biocon focus on innovation and quality is expected to help it maintain its growth in the coming years.

What is the Biocon share price target for 2030?

In 2030, Biocon is expected to trade in between ₹710.42 and ₹1,103.85.

Conclusion:

In conclusion, Biocon’s Q4 results and financial performance underscore the company’s strength and potential for future growth. Despite a temporary decline in net profit due to increased expenses, Biocon achieved significant annual revenue growth, reaching ₹15,621 crore for FY24. The Biologics segment’s billion-dollar milestone and strong market performance in key regions highlight the company’s strategic success.

Over the past five years, Biocon has consistently expanded its sales and operating profit, demonstrating robust financial health and operational efficiency. Strategic initiatives, including debt reduction and long-term collaborations, have further enhanced its market position.

Biocon’s unwavering commitment to innovation and global expansion positions it well for sustained growth. The company’s ability to adapt and thrive amidst challenges reinforces its potential to continue delivering value to stakeholders and making a significant impact on global healthcare.

Financesrule telegram

Author: Ashnoor

Leave a Reply